Loading...
XNAS
ZIVO
Market cap41mUSD
Jun 16, Last price  
11.00USD
1D
-21.37%
1Q
-38.20%
Jan 2017
-75.88%
IPO
-82.76%
Name

Zivo Bioscience Inc

Chart & Performance

D1W1MN
XNAS:ZIVO chart
P/E
—
P/S
266.82
EPS
—
Div Yield, %
—
Shrs. gr., 5y
42.73%
Rev. gr., 5y
%
Revenues
157k
+468.61%
95,967297,295161,340176,90379,14082,725103,8910000000020,0000027,650157,220
Net income
-13m
L+72.10%
-5,956,895-3,541,223-2,250,988-1,813,840-1,416,860-7,122,473-2,731,610-3,248,405-10,095,878680,811-5,789,131-6,059,627-10,038,374-14,635,367-14,667,982-9,655,783-9,396,647-8,745,293-7,777,184-13,384,836
CFO
-4m
L-25.63%
-1,649,480-2,089,257-1,406,740-935,823-1,150,119-1,439,727-1,294,128-1,773,264-2,986,213-2,736,046-2,296,887-2,543,473-4,242,891-5,006,586-3,707,297-2,588,415-6,803,333-7,102,612-5,799,893-4,313,510
Earnings
Aug 12, 2025

Profile

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is based in Bloomfield Hills, Michigan.
URL
https://zivobioscience.com/
IPO date
Oct 06, 2000
Employees
8
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
157
468.61%
28
 
Cost of revenue
13,519
7,291
8,732
Unusual Expense (Income)
NOPBT
(13,362)
(7,263)
(8,732)
NOPBT Margin
Operating Taxes
(4)
Tax Rate
NOPAT
(13,362)
(7,263)
(8,732)
Net income
(13,385)
72.10%
(7,777)
-11.07%
(8,745)
-6.93%
Dividends
Dividend yield
Proceeds from repurchase of equity
5,602
640
BB yield
-7.64%
-31.56%
Debt
Debt current
138
346
339
Long-term debt
116
106
311
Deferred revenue
Other long-term liabilities
Net debt
(1,288)
178
(1,149)
Cash flow
Cash from operating activities
(4,314)
(5,800)
(7,103)
CAPEX
Cash from investing activities
Cash from financing activities
5,582
4,275
(629)
FCF
(14,985)
(5,182)
46,491
Balance
Cash
1,542
274
1,799
Long term investments
Excess cash
1,535
273
1,799
Stockholders' equity
(136,963)
(123,579)
(115,795)
Invested Capital
136,702
121,720
116,230
ROIC
ROCE
5,128.62%
390.59%
EV
Common stock shares outstanding
3,410
1,690
1,570
Price
21.50
1,691.67%
1.20
-92.00%
15.00
-12.89%
Market cap
73,325
3,515.59%
2,028
-91.39%
23,549
7.55%
EV
72,036
2,206
22,400
EBITDA
(13,362)
(6,823)
(9,506)
EV/EBITDA
Interest
23
514
13
Interest/NOPBT